Metabolic and Bone Changes After Adjuvant Cancer Treatments in Early Non-metastatic Breast
Breast cancer is the most common cancer type in European women. Patients treated for early non-metastatic breast cancer comprise a growing group of survivors due to early diagnosis and improved treatment. Many of these survivors experience adverse effects such as decreased bone mineral density, derangement of metabolic
| Condition(s) | Bone Fracture, Glucose, High Blood, Insulin Resistance, Blood Pressure, High, Cholesterolemia |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Breast cancer is the most common cancer type in European women. Patients treated for early non-metastatic breast cancer comprise a growing group of survivors due to early diagnosis and improved treatment. Many of these survivors experience adverse effects such as decreased bone mineral density, derangement of metabolic markers (fat, glucose, insulin) and increased blood pressure. Increasing risk of bone fracture and cardiometabolic disease (eg. diabetes mellitus type 2). The purpose of this study is to identify mechanisms behind cardiometabolic changes that may be connected to the (neo-)adjuvant treatment. On top of this we hope to indentify potential biological markers that can help prevent development of metabolic disease. We will be recruiting 120 post-menopausal women age 50-70 with ea |
| Who can participate | Inclusion Criteria: * Postmenopausal * Breast cancer stage I-III * Eligible to receive (neo-)adjuvant chemotherapy/other antineoplastic treatment Exclusion Criteria: * Prior malignancy * Metabolic disease (diabetes mellitus etc) |
| Ages | 50 Years to 70 Years |
| Sex | Female |
| Lead sponsor | Rigshospitalet, Denmark |
| Locations | Copenhagen, Danmark, Denmark |
| Start date | 2018-12-17 |
| NCT ID | NCT03784651 |
| Official listing | https://clinicaltrials.gov/study/NCT03784651 |